Glaukos (GKOS) Financial Analysis & Valuation | Quarter Chart
Glaukos (GKOS)
GKOSPrice: $142.19
Fair Value: 🔒
🔒score
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outf... more
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the dev... more
Description
Shares
| Market Cap | $8.35B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Thomas William Burns |
| IPO Date | 2015-06-25 | CAGR | 0.51% |
| Employees | 995 | Website | www.glaukos.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
GKOS chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.97B | P/E Ratio | -165.34 |
| Forward P/E | 320.51 | PEG Ratio | — |
| P/S Ratio | 17.53 | P/B Ratio | 14.22 |
| P/CF Ratio | -1085.37 | P/FCF Ratio | -522.81 |
| EPS | $-0.86 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 36.3% | Gross Margin | 0.78% |
| Operating Margin | -0.16% | Profit Margin | -0.34% |
| ROE | -0.26% | ROA | -0.21% |
| ROCE | -0.11% | Current Ratio | 5.43 |
| Quick Ratio | 4.73 | Cash Ratio | 1.17 |
| Debt/Equity | 0.15 | Interest Coverage | -18.69 |
| Altman Z Score | 23.03 | Piotroski Score | 3 |